Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2017 After Market Close on March 13, 2017
06 mars 2017 08h05 HE
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2017 and Recent Developments
12 déc. 2016 16h05 HE
|
Peregrine Pharmaceuticals Inc.
-- Avid Posts Record Revenue of $23.4 Million During Second Quarter FY 2017 with Contracted Backlog of Future Business Currently at $73 Million -- -- Beta-2 Glycoprotein-1 (β2GP1) Identified as a...
Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2017 After Market Close on December 12, 2016
05 déc. 2016 16h05 HE
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
New Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals’ PS-Targeting Antibodies in a Preclinical Melanoma Model
14 nov. 2016 08h05 HE
|
Peregrine Pharmaceuticals Inc.
-- Promising Results of MSK Study Evaluating Combinations of PS-Targeting Treatment, Anti-PD-1 and Radiation in Mouse B16 Melanoma Model Presented at SITC 2016 -- -- New Data from Second Study...
Preclinical Research Demonstrates Peregrine Pharmaceuticals’ PS-Targeting Antibodies Enhance the Anti-Tumor Activity of PD-L1 Checkpoint Inhibitors in Model of Triple Negative Breast Cancer (TNBC)
24 oct. 2016 08h05 HE
|
Peregrine Pharmaceuticals Inc.
-- Combination of PS-Targeting Antibody and Anti-PD-L1 Therapy, With or Without Chemotherapy, Led to Greater Anti-Tumor Activity Than Single Agent Treatment or Dual Combinations With Chemotherapy -- ...
Peregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab in Oral Presentation at European Society for Medical Oncology (ESMO) 2016 Congress
10 oct. 2016 08h05 HE
|
Peregrine Pharmaceuticals Inc.
-- Company Has Identified Beta-2 Glycoprotein-1 (β2GP1) as a Biomarker that Correlates with Statistically Significant Improvement in Overall Survival for Patients Receiving the Bavituximab...
Peregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer (TNBC)
27 sept. 2016 08h05 HE
|
Peregrine Pharmaceuticals Inc.
-- Complete Tumor Regression Seen in 80% of Animals Treated with Triple Combination of PS-Targeting Antibody, Anti-PD-1 Therapy and Anti-Lag3 Therapy vs. 0% of Animals Receiving Double...
Peregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 Congress
21 sept. 2016 08h05 HE
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2017 and Recent Developments
08 sept. 2016 16h05 HE
|
Peregrine Pharmaceuticals Inc.
--SUNRISE Top-line Data Accepted for Late-Breaking Oral Presentation at European Society of Medical Oncology Congress in October 2016 -- -- Avid First Quarter Revenue of $5.6 Million with Over $20...
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
06 sept. 2016 16h05 HE
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...